The US has approved its first treatment for peanut allergies in children.

The drug AR101, or Palforzia, uses oral immunotherapy, with children given tiny but increasing amounts of peanut protein over a six-month period under medical supervision.【官方首页】-新疆体彩网这个药物叫作AR101,或Palforzia,采用口服免疫疗法,六个月的医学观察期内可以给儿童少量花生蛋白,并逐渐加量。

After that, users must continue to take a daily dose to be able to tolerate accidental exposure.

The treatment is not a cure and makers warn that the risk of a potentially fatal anaphylactic reaction remains.

And patients must continue to avoid peanuts in their diet.

Peanuts are the most common food allergen in the US, with an increase in the number of those affected by food allergies across the West in recent decades.

While trials to desensitise patients with peanut allergies have previously taken place in the US and elsewhere, the drug is the first to be approved by the US Food and Drug Administration (FDA). The drug has not yet been authorised for use in the UK.【官方首页】-新疆体彩网虽然此前美国和其他地区进行过花生过敏患者的脱敏试验,但这是首个经美国食品药品监督管理局批准的药品,但在英国尚未获准使用。

Palforzia, which has been approved for use in patients aged between four and 17, comes in the form of a powder which is sprinkled on food.

Last year, scientists at King's College London said that oral immunotherapy offered "protection but not a cure" for peanut allergies, with treatment only effective while patients continued taking small amounts of the allergen.